

TABLE OF CONTENTS

Chapter 1	1
1.1. Introduction	2
1.2. Research envisaged	8
1.3. References	10
Chapter 2	13
2.1. Intracellular Drug Delivery	14
2.1.1. Mechanisms of Intracellular Delivery	15
2.1.2. Barriers to Intracellular Delivery of Therapeutic Agents	15
2.1.3. Intracellular Targets	16
2.2. Intracellular Drug Delivery Approaches	17
2.2.1. Viral Vectors	17
2.2.2. Cationic Lipids and Polymers (Lipoplexes/polyplexes)	18
2.2.3. Micelles	18
2.2.4. Protein Transduction Domains	19
2.2.5. Nanoparticles	20
2.2.6. Liposomes	35
2.2.7. Super critical fluid technology	48
2.2.8. Polymer conjugates	61
2.3. Breast Cancer	78
2.3.1. Introduction of breast cancer	79
2.3.2. Risk Factors	81
2.3.3. Breast Abnormalities	84
2.3.4. Symptoms	88
2.3.5. Diagnosis	88
2.3.6. Prognosis	94
2.3.7. Cancer Stage and Treatment Options	98
2.4. Drug Profile of Docetaxel	115
2.5. References	128
Chapter 3	140
3.1. Introduction	141
3.2. Materials and Equipments	141
3.3. Chemical analysis	143
3.3.1. Estimation of Docetaxel	143
3.3.1.1. Estimation of DC	143
3.3.1.2. Estimation of docetaxel in NPs	145
3.3.1.3. Estimation of docetaxel for in-vitro release	145
3.4. Estimation of residual PVA	145
3.5. Determination of residual dichloromethane in NPs	146
3.6. Determination of peptide (RGD) by BCA method	147
3.6.1. Estimation of Phosphatidyl Choline	150
3.6.1.1. Solutions	150
3.6.1.2. Procedure for calibration curve	150
3.6.1.3. Stability and selectivity	151
3.6.1.4. Estimation of phosphatidyl choline from liposomes/ supernatant	152
3.6.2. Estimation of cholesterol	152
3.6.2.1. Solutions	152
3.6.2.2. Procedure for calibration curve	153

3.6.2.3 Stability and selectivity.....	153
3.6.2.4. Estimation of cholesterol from liposomes/ supernatant.....	153
3.7 Determination of Particle Size, Polydispersity and Zeta potential	154
3.8 Morphological characterization	155
3.9 Differential scanning calorimetry	155
3.10. Discussions	155
3.11. Rferences	158
Chapter 4	160
4.1. Introduction.....	161
4.2. Methods.....	162
4.2.1. Preparation of Liposomes by Supercritical Carbon dioxide (SC-CO ₂)	162
4.2.2. Apparatus	163
4.3. Optimization of Process Parameters	163
4.4. Optimization of Formulation Parameters.....	167
4.5. Preparation of Nanoparticles.....	179
4.5.1. Method of Preparation	180
4.5.2. Optimization of process variables:.....	181
4.5.3. Method of Preparation using solvent diffusion technique	183
4.5.4. Optimization of formulation parameters.....	184
4.5.5. Response surface and countour plots for Solvent evaporation method	185
4.5.6. Response surface and countour plots for nanoprecipitation method	188
4.6. Lyophilization and optimization of cryoprotectant concentration.....	194
4.7. RGD attachment to PLGA nanoparticles.....	194
4.8. Preparation of 6-coumarin loaded nanoparticles	197
4.9. Results and discussion	198
4.9.1. Preparation of liposomes by supercritical fluid technology	198
4.9.2. Preparation of Nanoparticles by SOLVENT EVAPORATION	203
4.9.3. Preparation of Nanoparticles by Nanoprecipitation.....	205
4.9.4. Lyophilization of Nanoconstructs.....	207
4.9.5. RGD conjugation of nanoparticles and Liposomes	210
4.10. Conclusions.....	213
4.11. References.....	214
Chapter 5	218
5.1. Introduction.....	219
5.2. Methods.....	221
5.2.1. Particle size and zeta potential.....	221
5.2.3. In-vitro drug release.....	221
5.2.3. Transmission electron microscopy	222
5.2.4. Surface morphology.....	222
5.2.5 X- ray diffraction studies (XRD)	222
5.2.6. Differential Scanning Colorimetry	222
5.2.7. Determination of residual PVA	223
5.2.8. [1H]NMR of the RGD conjugated nanoconstructs.....	223
5.2.9 Infrared spectra of nanoparticles.....	223
5.3. Results and Discussion	223
5.3.1. Particle size, zeta potential and drug entrapment efficiency.....	223
5.3.2. In-vitro Drug Release.....	226
5.3.3. Transmission Electron Microscopy	229
5.3.4. Scanning Electron Microscopy	230
5.2.5. X- ray diffraction studies (XRD)	231

5.3.6. Differential Scanning Calorimetry.....	232
5.3.7. ¹ H]NMR of the RGD conjugated nanoconstructs.....	233
5.3.8. Infrared spectra of nanoparticles.....	236
5.3.9. Residual PVA.....	237
5.3.10. Characterization of 6-coumarin nanoparticles.....	237
5.4. Conclusions.....	239
5.5. References:.....	240
Chapter 6	242
6.1. Introduction.....	243
6.2. Methodology	244
6.3. Results and Discussions.....	245
6.4. Conclusions.....	252
6.5. References.....	253
Chapter 7	255
7.1. Introduction.....	256
7.2. Methods.....	260
7.2.1. Intracellular uptake studies	260
7.2.2. In-vitro Cytotoxicity Studies.....	261
7.2.3. DNA content anlaysis by flow cytometry.....	262
7.2.4. Apoptosis and Necrosis study.....	262
7.2.5. Histological study by TEM.....	263
7.3. Results and Discussion	263
7.3.1. Intracellular uptake of Nanoparticles.....	263
7.3.2. Fluorescent microscopy	266
7.3.3. In-vitro Cytotoxicity Studies.....	268
7.3.4. Cell cycle study.....	282
7.3.5. Apoptosis and Necrosis study.....	288
7.3.6. Histology study by TEM.....	294
7.4. Conclusions.....	295
7.5. References.....	296
Chapter 8	299
8.1. Introduction.....	300
8.2. Preparation of copolymer.....	301
8.2.1. Preparation of HPMA monomer.....	301
8.2.2. Preparation of MA-GF-OH.....	302
8.2.3. Synthesis LG-OMe.HCl.....	302
8.2.4. Synthesis of MA-GFLG-OMe	303
8.2.5. Synthesis of MAGFLG-OH.....	304
8.2.6. Synthesis of MA-GG-OH	304
8.2.7. Synthesis of MA-GG-ONp	304
8.2.8. Synthesis of MA-Tyr-OMe.....	305
8.2.9. Synthesis of MA-GFLG-Docetaxel	305
8.2.10. Polymerization of co-monomers.....	306
8.2.11. Attachment of RGDfk:.....	307
8.3. In vitro evaluation of HPMA-docetaxel- RGDfk copolymer conjugates.....	308
8.3.1. Characterization of comonomers by Mass spectrometry.....	308
8.3.2. Characterization of comonomers by NMR.....	308
8.3.3. Determination of drug content.....	308

8.3.4. Determination of ONp content.....	308
8.3.5. Determination of Molecular weight of the copolymer	308
8.3.6. Determination of peptide content.....	309
8.3.7. Drug release studies	309
8.3.8. In vitro cytotoxicity assay	309
8.3.9. DNA Content Analysis study by Flowcytometer	310
8.3.10. Confocal Microscopy.....	310
8.3.11. Stability studies in mice serum and PBS pH 7.4	310
8.4. Results and Discussion	310
8.4.1. Characterization of monomers by Mass spectrometer.....	310
8.4.2. Characterization of drug attachment by NMR.....	316
8.4.3. Determination of drug, peptide content and molecular weight of copolymer.....	318
8.4.4. Cathepsin B catalyzed drug release from HPMA copolymer-DC conjugates	319
8.4.5. In vitro growth inhibition.....	320
8.4.6. DNA Content Analysis study by Flowcytometry	321
8.4.7. Confocal Microscopy.....	323
8.4.8 Stability study	324
8.4. Discussion:.....	326
8.5. Conclusions.....	327
8.6. References.....	328
Chapter 9	330
9.1. Summary	331
9.2. Conclusions.....	345